According to the FDA, 2/3 of their spending on human drug regulation is covered by user fees. Given that some or most of the rest must be non-approval related (

According to the FDA, 2/3 of their spending on human drug regulation is covered by user fees. Given that some or most of the rest must be non-approval related (ongoing supervision and overhead), and the approval work doesn't go away if they delay it, I'd guess that they have the resources to evaluate as many trials as are ongoing. https://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance https://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glan...